Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis (MS) - Relapsing-remitting Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Tovaxin Autologous T cell vaccine, Placebo
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced May 22, 2026, 5:45 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex® monotherapy (6.0 MIU administered i.m. each week)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced May 22, 2026, 5:45 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, BMS 188667 (Abatacept)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2010 · Synced May 22, 2026, 5:45 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
East Hanover, New Jersey • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced May 22, 2026, 5:45 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Motivational Interviewing-Cognitive Behavioral Therapy, Brief Education
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Kansas City, Missouri • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced May 22, 2026, 5:45 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Step Tracking, Water Tracking
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 59 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced May 22, 2026, 5:45 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MSDx Complex-1 Biomarker Test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced May 22, 2026, 5:45 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood sample collection for coagulation profile
Diagnostic Test
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced May 22, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced May 22, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced May 22, 2026, 5:45 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Kansas City, Missouri • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced May 22, 2026, 5:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced May 22, 2026, 5:45 AM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
3 mg Melatonin, 5 mg Melatonin
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced May 22, 2026, 5:45 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 22, 2026, 5:45 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
38
States / cities
Homewood, Alabama • Tucson, Arizona • Colorado Springs, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced May 22, 2026, 5:45 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced May 22, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions
wearable focal vibration therapy
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 22, 2026, 5:45 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced May 22, 2026, 5:45 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Interventions
Closed Loop Trans-Auricular Vagus Nerve Stimulation System, Placebo
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced May 22, 2026, 5:45 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MS Care Platform (icobrain ms and icompanion ms)
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Golden Valley, Minnesota • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 5:45 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced May 22, 2026, 5:45 AM EDT